JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.

JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.

Accepted version

Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/286785

Repository DOI

https://doi.org/10.17863/CAM.34092

Files

Accepted version (172.28 KB)

Type

Authors

Gallipoli, Paolo

https://orcid.org/0000-0001-7254-2253

Keywords

Antineoplastic Agents, Humans, Janus Kinase 2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Nitriles, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines

Journal Title

Leuk Res

Journal ISSN

0145-2126
1873-5835

Volume Title

75

Publisher

Elsevier BV

Publisher DOI

https://doi.org/10.1016/j.leukres.2018.10.010

Rights and licensing

Except where otherwised noted, this item's license is described as http://www.rioxx.net/licenses/all-rights-reserved

Sponsorship

Medical Research Council (MC_PC_12009)
Wellcome Trust (109967/Z/15/Z)

Collections

University of Cambridge Research Outputs (Articles and Conferences)